November 21, 2019 -- Purolite Ltd. today announces that its Praesto agarose-based chromatography resin range is being utilized for the commercial manufacturing of FDA-approved biotherapeutics.
Purolite is a leading manufacturer of quality ion exchange, catalyst, adsorbent and specialty high-performance resins Praesto resins are an integral technology used by biopharmaceutical developers for the purification of modern medicines targeting the treatment of cancer, rheumatoid arthritis, dementia and diabetes.
"This is a major milestone for Purolite Life Sciences, and we are truly proud that our resin technology will be used by customers in FDA-approved commercial manufacturing processes," said Chris Major, Global Sales and Marketing Director for the Agarose division of Purolite Life Sciences."The adoption of our Praesto product range is a testament to our technology leadership, differentiating us from competitors with 'best in class' performance, shorter lead times, and a strong commitment to security of supply. Purolite has invested over $150 million into a global expansion program in recent years, as a continued commitment to resin innovation, including doubling the production capacity of our unique, uniform-bead jetting technology. We look forward to continuing to meet our customers' growing demand for this high-performance resin."
Purolite's latest investment to increase production capacity of its proprietary, uniform-particle-size manufacturing process comes just one year after opening one of the largest agarose-based resin manufacturing facilities in the world. Based in the UK, the facility boasts a 100,000L capacity, equivalent to 30% of annual global demand.